GLG Vital SignsSM: Post-ESMO Impact: Nexavar/Denosumab
Views from Ten Medical Oncologists
Reactions from ten top medical oncologists, powered by the GLG Healthcare CouncilsSM, regarding data presented by Amgen and Bayer at the 34th European Society of Medical Oncology (ESMO) Congress in Berlin the week of September 21, 2009. Respondents included top medical oncologists from leading institutions in the United States and Europe who specialize in breast cancer treatment. These physicians include clinicians treating breast cancer, principal investigators on past breast cancer clinical trials, and thought leaders who have published widely on targeted therapeutics for the disease
GLG Vital Signs Questions:
- Please discuss your thoughts on the data released at the European Society for Medical Oncology (ESMO) Congress on Nexavar.
- Please discuss your thoughts on the data released at ESMO on Denosumab.
- How do you believe the latest data presented on Nexavar and Denosumab above and the upcoming full releases at ESMO will affect the overall prescription of these drugs?
Read the full report:
Request information on GLG solutions for your firm
About GLG Vital Signs
GLG Vital Signs are quick-turnaround Q&A reports, powered by the GLG Q&A tool and the GLG CouncilsSM, about publicly available news and issues. GLG Vital Signs are meant to offer rapidly-delivered insights from key thought and opinion leaders from the GLG Councils. GLG Vital Signs are available for purchase. GLG clients can commission custom Q&A reports by providing GLG with unique questions for GLG Council Member populations. Contact GLG for more information.
GLG Vital Signs and Q&A responses are solely the work of the respondents and have not been edited or endorsed by GLG.